Iván Pérez-Gutiérrez

Mr. Iván Pérez-Gutiérrez

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SRStefano Ruberto
Stefano Ruberto
MRMelanie Rojas-Salazar
Melanie Rojas-Salazar
MDMaría I. Domínguez-Mozo
María I. Domínguez-Mozo
MNMaría Núñez-Orantos
María Núñez-Orantos
NCNoemi Cabello-Clotet
Noemi Cabello-Clotet
RÁRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
Multiple sclerosis (MS) and human immunodeficiency virus (HIV) rarely co-occur, suggesting HIV-mediated modulation of MS-related viral immunopathology. This multicentre cross-sectional study analyzed 14 individuals with MS + HIV (HIV → MS, n = 4; MS → HIV, n = 10), alongside HIV-positive individuals on antiretroviral therapy (ART, n = 21), MS (n = 21; 18 on disease-modifying therapies DMTs), and healthy controls (n = 21). IgG/IgM responses to Epstein–Barr virus (EBV), Cytomegalovirus (CMV), human herpesvirus-6 (HHV-6), and human endogenous retrovirus-W envelope (HERV-W env) were quantified by ELISA. HERV-W env expression in PBMC subsets was assessed by FACS/qPCR and flow cytometry (monoclonal antibody CALI222B). Discriminant function analysis (DFA) was used to evaluate a preliminary cohort classification. MS + HIV cohorts displayed higher CMV IgG seroprevalence (95–100% vs. 45% in MS; OR 24.4) and titres. EBNA-1 IgG prevailed in MS and MS + HIV (95–100% vs. 67% in HIV). HERV-W expression was reduced in HIV versus MS, particularly in HIV → MS. Exploratory DFA classified cohorts with 79.6% accuracy (CMV/EBNA-1 primary discriminators). Stepwise analysis identified CMV, EBNA-1, and EBV VCA IgG as main predictors, achieving 100% classification accuracy for MS + HIV (76.4% overall). CMV-dominated profiles distinguish MS + HIV comorbidity, with HIV/ART-associated suppression of EBV/HHV-6 humoral responses and HERV-W gene expression, suggesting an immune remodeling that may explain reduced MS prevalence among people living with HIV.

Verified
Journal Article
Open access
PDF file
IJInés Jiménez
Inés Jiménez
MCMartín Cuesta-Hernández
Martín Cuesta-Hernández
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
IPIván Pérez-Gutiérrez
Iván Pérez-Gutiérrez
SRStefano Ruberto
Stefano Ruberto
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
Type 1 Diabetes (T1D) is thought to result from the interaction of genetic and environmental factors, with different studies highlighting a potential role for the gut microbiota and its metabolites in modulating immune responses and disease development. We hypothesized that patients with T1D exhibited altered levels of circulating bacterial metabolites compared with healthy controls (HC), and that these metabolite profiles were associated with key demographic, clinical, and analytical features of the disease. A total of 91 T1D patients and 58 HC were recruited. Plasma samples were collected and analyzed with gas chromatography coupled to mass spectrometry for the detection of the metabolites: short-chain fatty acids (SCFAs: acetate [AA], propionate [PA], isobutyrate [IBA], butyrate [BA], isovalerate [IVA], valerate [VA], and methyl valerate [MVA]), medium-chain fatty acids (MCFAs: hexanoate [HxA] and heptanoate [HpA]) and para-cresol (p-cresol). We also calculated the ratios between the different SCFAs with AA. T1D patients showed significantly higher circulating AA levels than HC, along with reduced PA/AA and IBA/AA ratios, indicating an altered SCFA profile. SCFA diversity was lower in T1D patients, with reduced detection of BA, and total SCFA levels were increased mainly due to elevated AA. AA levels were higher and SCFA ratios lower in women with T1D compared with healthy women, while p-cresol levels were higher in men with T1D than in healthy men. In T1D patients, AA levels positively correlated with HbA1c, whereas PA/AA, IBA/AA, and BA/AA ratios showed negative correlations, particularly in women. MV/AA and non-AA/AA ratios were inversely associated with glucose levels, again, mainly in women. p-cresol levels correlated positively with age and ferritin and were higher in T1D patients with liver dysfunction or hypertension. Therefore, we can conclude that T1D is associated with a marked alteration in circulating gut-derived metabolites, characterized by increased AA levels, particularly in women, and an imbalance in SCFA ratios that correlates with glycemic control. These findings, together with the associations observed for p-cresol and metabolic comorbidities, support a role for the gut microbiota–host metabolic axis in T1D.

11 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
IJInés Jiménez
Inés Jiménez
MCMartín Cuesta-Hernández
Martín Cuesta-Hernández
MDMaría Inmaculada Domínguez-Mozo
María Inmaculada Domínguez-Mozo
IPIván Pérez-Gutiérrez
Iván Pérez-Gutiérrez
SRStefano Ruberto
Stefano Ruberto
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
INTRODUCTION: While the exact cause of Type 1 Diabetes (T1D) remains unclear, it is widely believed that both genetic and environmental factors contribute to the development of the disease. Recent research has explored the potential role of gut microbiota and its metabolites in modulating immune responses and influencing the development of autoimmune diseases like T1D. With this purpose, we designed a study: 1. to compare the levels of different bacterial metabolites in plasma samples of T1D patients and healthy controls (HC). 2. to correlate the levels of these metabolites with different demographic, clinical and analytical variables collected from the T1D patients. METHODS: A total of 91 T1D patients were recruited. Plasma samples were collected and analyzed with gas chromatography coupled to mass spectrometry for the detection of the metabolites: short-chain fatty acids (SCFA: acetate [AA], propionate [PA], isobutyrate [IBA], butyrate [BA], isovalerate [IVA], valerate [VA] and methyl valerate [MVA]), medium-chain fatty acids (MCFA: hexanoate [HxA] and heptanoate [HpA]) and para-cresol (p-cresol). We also calculated the ratios between the different SCFA with AA. RESULTS: 1. AA levels were significantly higher in T1D patients than in HC (p=0.0009). PA/AA and IBA/AA ratios were significantly higher in HC (p=0.0004 and p=0.0001, respectively). 2. Glycated haemoglobin (HbA1c) was positively correlated with AA levels (p=0.0001; r=0.406) and a significant negative correlation with a rSpearman< -0.3 was found for PA/AA, IBA/AA and BA/AA ratios. 3. p-cresol correlated with Ferritin levels (p=0.04; r=0.362); besides, p-cresol levels were lower in T1D patients with a normal liver profile (p=0.002) and in T1D patients without hypertension (p=0.005). CONCLUSIONS: Serum levels of bacterial metabolites were significantly different in T1D patients. AA levels were significantly increased in T1D patients and p-cresol was higher in T1D patients with liver disturbances and hypertension. To develop strategies to restore gut microbiota health and immune balance could be essential for the control of T1D.